0 172

Cited 0 times in

Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study

DC Field Value Language
dc.date.accessioned2023-06-02T01:14:11Z-
dc.date.available2023-06-02T01:14:11Z-
dc.date.issued2022-11-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194753-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleTelisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorH. Horinouchi-
dc.contributor.googleauthorJ.W. Goldman-
dc.contributor.googleauthorB.C. Cho-
dc.contributor.googleauthorP. Tomasini-
dc.contributor.googleauthorM. Dunbar-
dc.contributor.googleauthorD. Hoffman-
dc.contributor.googleauthorA. Parikh-
dc.contributor.googleauthorV. Blot-
dc.contributor.googleauthorD.R. Camidge-
dc.identifier.doi10.1016/j.annonc.2022.10.424-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422046154-
dc.citation.volume33-
dc.citation.numberSuppl 9-
dc.citation.startPageS1592-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(Suppl 9) : S1592, 2022-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.